Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Arcutis Biotherapeutics Inc
Operating Expenses
Arcutis Biotherapeutics Inc
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
Operating Expenses
-$295.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$20.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Arcutis Biotherapeutics Inc's Operating Expenses?
Operating Expenses
-295.7m
USD
Based on the financial report for Dec 31, 2023, Arcutis Biotherapeutics Inc's Operating Expenses amounts to -295.7m USD.
What is Arcutis Biotherapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-72%
Over the last year, the Operating Expenses growth was 3%. The average annual Operating Expenses growth rates for Arcutis Biotherapeutics Inc have been -29% over the past three years , -72% over the past five years .